Medical Coverage Policy

Wearable and Portable Cardioverter-Defibrillators-PREAUTH

☐ Device/Equipment  ☐ Drug  ☐ Medical  ☒ Surgery  ☐ Test  ☐ Other

Effective Date: 01/17/2012  Policy Last Updated: 1/17/2012

☑ Prospective review is recommended/required. Please check the member agreement for preauthorization guidelines.

☐ Prospective review is not required.

This policy addresses the use of wearable and portable defibrillators only and does not include an implantable defibrillator as they are covered.

Description:
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. The implantable cardioverter-defibrillator (ICD) has proven effective in reducing mortality for survivors of SCA and for patients with documented malignant ventricular arrhythmias. More recently, the use of ICDs has been potentially broadened by studies reporting a reduction in mortality for patients at risk for ventricular arrhythmias, such as patients with prior myocardial infarction (MI) and reduced ejection fraction. ICDs consist of implantable leads in the heart that connect to a pulse generator implanted beneath the skin of the chest or abdomen. ICD placement is a minor surgical procedure, with the ICD device placed under the skin on the chest wall and the cardiac leads placed percutaneously. Potential adverse effects of ICD placement are bleeding, infection, pneumothorax, and delivery of unnecessary counter shocks.

The wearable cardioverter-defibrillator (WCD) is an external device that is intended to perform the same tasks as an ICD, without requiring invasive procedures. It consists of a vest that is worn continuously underneath the patient's clothing. Part of this vest is the 'electrode belt' that contains the cardiac-monitoring electrodes and the therapy electrodes that deliver a counter shock. The vest is connected to a monitor with a battery pack and alarm module that is worn on the patient's belt. The monitor contains the electronics that interpret the cardiac rhythm and determines when a counter shock is necessary. The alarm module alerts the patient to certain conditions by lights or voice messages.

The U.S. Food and Drug Administration (FDA) approved the Lifecor WCD® 2000 system via premarket application approval in December 2001 for “adult patients who are at risk for cardiac arrest and are either not candidates for or refuse an implantable defibrillator.”

A nonwearable external defibrillator is a portable device that is used by someone other than the affected individual to effect defibrillation. It consists of a monitor, electrodes, and a small alarm module.

Medical Criteria:
WEARABLE DEFIBRILLATORS

Wearable external defibrillators are covered for patients at high risk for sudden cardiac death (SCD) due to one of the conditions described under I or II (criteria in portable defibrillators). It is expected the ordering physician be experienced in the management of patients at risk for SCD.

I. A wearable defibrillator (K0606) is covered for patients if they meet one of the criteria (1-4):
   1. A documented episode of ventricular fibrillation or a sustained, lasting 30 seconds or longer, ventricular tachyarrhythmia. These dysrhythmias may be either spontaneous or induced during an electrophysiologic (EP) study, but may not be due to a transient or reversible cause and not occur during the first 48 hours of an acute myocardial infarction; or
   2. Familial or inherited conditions with a high risk of life-threatening ventricular tachyarrhythmia such as long QT syndrome or hypertrophic cardiomyopathy; or
   3. Either documented prior myocardial infarction or dilated cardiomyopathy and a measured left ventricular ejection fraction less than or equal to 0.35; or
   4. A previously implanted defibrillator now requires explantation.

PORTABLE DEFIBRILLATORS

II. A portable external defibrillator (E0617) is covered for patients in two circumstances. They meet either both criteria A and B or criteria C, described below:

   A. The patient has one of the following conditions (1-8):
      1. A documented episode of cardiac arrest due to ventricular fibrillation, not due to a transient or reversible cause.
      2. A sustained, lasting 30 seconds or longer, ventricular tachyarrhythmia, either spontaneous or induced during an electrophysiologic (EP) study, not associated with acute myocardial infarction, and not due to a transient or reversible cause.
      3. Familial or inherited conditions with a high risk of life-threatening ventricular tachyarrhythmias such as long QT syndrome or hypertrophic cardiomyopathy.
      4. Coronary artery disease with a documented prior myocardial infarction, with a measured left ventricular ejection fraction less than or equal to 0.35, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) during an EP study. To meet this criterion:
         a. The myocardial infarction must have occurred more than 4 weeks prior to the external defibrillator prescription; and,
         b. The EP test must have been performed more than 4 weeks after the qualifying myocardial infarction.
5. Documented prior myocardial infarction and a measured left ventricular ejection fraction less than or equal to 0.30. Patients must not have:
   a. Cardiogenic shock or symptomatic hypotension while in a stable baseline rhythm; or
   b. Had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within past 3 months; or
   c. Had an enzyme-positive MI within past month; or
   d. Clinical symptoms or findings that would make them a candidate for coronary revascularization; or
   e. Irreversible brain damage from preexisting cerebral disease; or
   f. Any disease, other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than one year.

6. Patients with ischemic dilated cardiomyopathy (IDCM), documented prior myocardial infarction (MI), New York Heart Association (NYHA) Class II and III heart failure, and measured left ventricular ejection fraction (LVEF) ≤ 35%.

7. Patients with nonischemic dilated cardiomyopathy (NIDCM) > 3 months, NYHA Class II and III heart failure, and measured LVEF ≤ 35%.

8. Patients who meet one of the previous criteria (1-7) and have NYHA Class IV heart failure.

B. Implantation surgery is contraindicated.

C. A previously implanted defibrillator now requires removal.

Claims for defibrillators for other indications will be denied as not reasonable and necessary.

**NOTE:** Medicare policy is developed separately from BCBSRI policy. Medicare policy incorporates scientific evidence with local expert opinion, and consideration of governmental regulations from CMS (Centers for Medicare and Medicaid Services), such as national coverage determinations or local coverage determinations. and the US Congress. BCBSRI policy is based upon peer-reviewed, scientifically controlled studies in the literature that demonstrate the superior health outcome of a service or treatment. In addition to benefit differences, CMS may reach different conclusions regarding the scientific evidence than does BCBSRI. BCBSRI and Medicare policies may differ, however, our BlueCHiP for Medicare members must be offered, at least, the same services as Medicare offers. (In some, but not all instances, BCBSRI offer more benefits than does Medicare).

**Commercial Products only**

**WEARABLE DEFIBRILLATORS**

Wearable Cardioverter-Defibrillators are only covered as a bridge to implantable cardioverter-defibrillator placement when the following indications have been met:
Use of wearable cardioverter-defibrillators for the prevention of sudden cardiac death is considered medically necessary as interim treatment for those who have all of the following:

- Meet the criteria for an implantable cardioverter-defibrillator;
  - Ischemic cardiomyopathy
  - Nonischemic dilated cardiomyopathy
  - Hypertrophic cardiomyopathy (HCM); and

- Have a temporary contraindication to receiving an ICD, such as a systemic infection, at the current time; and

- Have been scheduled for an ICD placement or who had an ICD removed and have been rescheduled for placement of another ICD once the contraindication is treated.

Use of wearable cardioverter-defibrillators for the prevention of sudden cardiac death is considered not medically necessary for all other indications, including use immediately (i.e., less than 40 days) following an acute myocardial infarction because the evidence does not support the conclusion that the WCD improves outcomes.

**PORTABLE DEFIBRILLATORS**

A portable external defibrillator (E0617) is covered for patients in two circumstances. They meet **either both criteria A and B or criteria C**, described below:

**A.** The patient has one of the following conditions (1-8):

1. A documented episode of cardiac arrest due to ventricular fibrillation, not due to a transient or reversible cause.
2. A sustained, lasting 30 seconds or longer, ventricular tachyarrhythmia, either spontaneous or induced during an electrophysiologic (EP) study, not associated with acute myocardial infarction, and not due to a transient or reversible cause.
3. Familial or inherited conditions with a high risk of life-threatening ventricular tachyarrhythmias such as long QT syndrome or hypertrophic cardiomyopathy.
4. Coronary artery disease with a documented prior myocardial infarction, with a measured left ventricular ejection fraction less than or equal to 0.35, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) during an EP study. To meet this criterion:
   - The myocardial infarction must have occurred more than 4 weeks prior to the external defibrillator prescription; and,
   - The EP test must have been performed more than 4 weeks after the qualifying myocardial infarction.
5. Documented prior myocardial infarction and a measured left ventricular ejection fraction less than or equal to 0.30. Patients must not have:
   - Cardiogenic shock or symptomatic hypotension while in a stable baseline rhythm; or
b. Had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within past 3 months; or
c. Had an enzyme-positive MI within past month; or
d. Clinical symptoms or findings that would make them a candidate for coronary revascularization; or
e. Irreversible brain damage from preexisting cerebral disease; or
f. Any disease, other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than one year.

6. Patients with ischemic dilated cardiomyopathy (IDCM), documented prior myocardial infarction (MI), New York Heart Association (NYHA) Class II and III heart failure, and measured left ventricular ejection fraction (LVEF) ≤ 35%.
7. Patients with nonischemic dilated cardiomyopathy (NIDCM) > 3 months, NYHA Class II and III heart failure, and measured LVEF ≤ 35%.
8. Patients who meet one of the previous criteria (1-7) and have NYHA Class IV heart failure.

II. Implantation surgery is contraindicated.
III. A previously implanted defibrillator now requires removal.

Policy:

Preauthorization is required for Blue CHiP for Medicare and recommended for all other BCBSRI products.

BlueCHiP for Medicare members
Wearable external defibrillators are covered for patients at high risk for sudden cardiac death (SCD) are covered when the medical criteria for BlueCHiP for Medicare above are met.

BlueCHiP for Medicare and Commercial product members
Portable automatic external defibrillators are covered when the medical criteria for BlueCHiP for Medicare above are met.

Commercial product members
Wearable cardioverter-defibrillators as a bridge to implantable cardioverter-defibrillator placement are covered when the medical criteria above are met.

NOTE: At the present time, Zoll LifeVest is the only provider of wearable defibrillators, and as they are non-participating, out of network copays can be waived when a request is determined to be medically necessary.

Coverage:
Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for the applicable Durable Medical Equipment coverage.

Codes:
The following codes require preauthorization:
K0606 Automatic external defibrillator, with integrated electrocardiogram analysis, garment type
E0617 External defibrillator with integrated electrocardiogram analysis (portable)

The following code will only pay when there is an approved rental on HCPCS code K0606.

93745 Initial set-up and programming by a physician of wearable cardioverter-defibrillator includes initial programming of system, establishing baseline electronic electrocardiogram, transmission of data to data repository, patient instruction in wearing system and patient reporting of problems or events

The following codes are covered and do not require preauthorization:

K0607 Replacement battery for automated external defibrillator, each  no preauth
K0608 Replacement garment for use with automated external defibrillator, each  no preauth
K0609 Replacement electrodes for use with automated external defibrillator, each  no preauth
93292 Interrogation device evaluation (in person) with physician analysis, review and report, includes connection, recording and disconnection per patient encounter; wearable defibrillator system  no preauth

Related Topics:
Total Artificial Hearts as Permanent Replacement Therapy

Published:
Provider Update, March 2012

References:


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice.